Sanofi, in partnership with Regeneron, had been testing the drug’s effects against COVID-19 because the drug is proven to curb inflammation. But the drug didn’t significantly shorten patients’ hospital stays in a study involving 420 people, Sanofi said.
Sanofi said patients were just about as likely to develop severe infections and die while on Kevzara as they were on a placebo.
Sanofi CEO Paul Hudson has said Kevzara was a “long shot” as a treatment against COVID-19, according to Bloomberg.
Regeneron is also testing an antibody drug cocktail it has developed specifically for COVID-19.
More articles on pharmacy:
Mylan recalls 2 drugs after label mix-up
Novartis establishes new sustainability goals
Bayer to acquire vitamin subscription company for $225M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.